


Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the *FMR1* Gene

Graphical Abstract



Authors

X. Shawn Liu, Hao Wu, Marine Krzisch, ..., Angela Cacace, Richard A. Young, Rudolf Jaenisch

Correspondence

jaenisch@wi.mit.edu

In Brief

Rescue of fragile X syndrome neurons by CRISPR-mediated DNA methylation editing of the *FMR1* gene.

Highlights

- Targeted demethylation of CGG repeats by dCas9-Tet1 reactivates *FMR1* in FXS cells
- Demethylation of CGG repeats induces an active chromatin status for *FMR1* promoter
- Methylation-edited FXS neurons behave similarly as wild-type neurons
- *FMR1* reactivation by dCas9-Tet1 is sustainable in a human/mouse chimeric model



Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the *FMR1* Gene

X. Shawn Liu,¹ Hao Wu,^{1,3} Marine Krzisch,¹ Xuebing Wu,¹ John Graef,³ Julien Muffat,¹ Denes Hnisz,¹ Charles H. Li,^{1,2} Bingbing Yuan,¹ Chuanyun Xu,^{1,5} Yun Li,¹ Dan Vershkov,⁴ Angela Cacace,³ Richard A. Young,^{1,2} and Rudolf Jaenisch^{1,2,6,*}

¹Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA

²Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA

³Fulcrum Therapeutics, One Kendall Square, Binney Street b7102, Cambridge, MA 02139, USA

⁴The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 91904, Israel

⁵Present address: Department of Biology, Stanford University, Stanford, CA 94305, USA

⁶Lead Contact

*Correspondence: jaenisch@wi.mit.edu

<https://doi.org/10.1016/j.cell.2018.01.012>

SUMMARY

Fragile X syndrome (FXS), the most common genetic form of intellectual disability in males, is caused by silencing of the *FMR1* gene associated with hypermethylation of the CGG expansion mutation in the 5' UTR of *FMR1* in FXS patients. Here, we applied recently developed DNA methylation editing tools to reverse this hypermethylation event. Targeted demethylation of the CGG expansion by dCas9-Tet1/single guide RNA (sgRNA) switched the heterochromatin status of the upstream *FMR1* promoter to an active chromatin state, restoring a persistent expression of *FMR1* in FXS iPSCs. Neurons derived from methylation-edited FXS iPSCs rescued the electrophysiological abnormalities and restored a wild-type phenotype upon the mutant neurons. *FMR1* expression in edited neurons was maintained *in vivo* after engrafting into the mouse brain. Finally, demethylation of the CGG repeats in post-mitotic FXS neurons also reactivated *FMR1*. Our data establish that demethylation of the CGG expansion is sufficient for *FMR1* reactivation, suggesting potential therapeutic strategies for FXS.

INTRODUCTION


Fragile X syndrome (FXS) is the most common genetic form of intellectual disability, with an incidence of one in 3,600 males. Patients with FXS display a broad spectrum of autistic phenotypes such as intellectual, cognitive, and social deficits (Contractor et al., 2015; Pugin et al., 2017; Santoro et al., 2012; Sidorov et al., 2013). These deficits are attributed to the loss of the fragile X mental retardation protein (FMRP) encoded by the *FMR1* gene during brain development. FMRP is an RNA binding protein in neurons and has been shown to be a molecular brake for local protein synthesis at developing synapses and, hence, is essential for the maintenance of normal synaptic plasticity (Darnell et al., 2011; Sidorov et al., 2013; Smith et al., 2014). Indeed, loss of FMRP expression in patient-derived neurons leads to

deregulated production and membrane insertion of neurotransmitter receptors and ion channels, causing synaptic hyper-excitability that affects the proper function of various neural circuits in the CNS (Contractor et al., 2015; Irwin et al., 2000; Santoro et al., 2012). A CGG trinucleotide repeat (> 200) expansion mutation at the 5' UTR of *FMR1*, accompanied by DNA hypermethylation, was thought to result in heterochromatin formation at the *FMR1* promoter and subsequent silencing of *FMR1* expression in FXS (Avitzour et al., 2014; Coffee et al., 1999; Colak et al., 2014; de Esch et al., 2014; Halevy et al., 2015; Urbach et al., 2010; Verkerk et al., 1991), but the molecular mechanism are not fully understood.

Currently, there is no cure or treatment for FXS, likely because of the lack of a mechanistic understanding of FXS pathophysiology at the molecular and cellular level and the enormous complexity of the FXS neuronal circuitry phenotype (Contractor et al., 2015; Santoro et al., 2012). Insertion of CGG repeats into the mouse *Fmr1* locus did not result in DNA hypermethylation or repression of *Fmr1* expression (Berman et al., 2014). Although *Fmr1* knockout (KO) mice partially recapitulate the neuronal hyper-excitability and excessive spinogenesis in the brain (The Dutch-Belgian Fragile X Consortium, 1994; Bernardet and Crusio, 2006; Comery et al., 1997; Huber et al., 2002), the FXS mouse model neither harbors the accurate genetic context nor fully recapitulates the phenotypes of FXS patients. For example, the PAK1 inhibitor and negative allosteric modulator for mGluR5 have been found to ameliorate synaptic functions in the *Fmr1* KO mouse model but have variable efficacy in FXS patients (Dolan et al., 2013; Dölen et al., 2007; Erickson et al., 2017; Hagerman et al., 2009; Hayashi et al., 2007; Michalon et al., 2012). Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) derived from FXS patients have been reported to properly model the hypermethylation of CGG repeats and the silencing of *FMR1* (Eiges et al., 2007; Urbach et al., 2010), representing a useful and complementary tool to study FXS.

The CRISPR/Cas9 system, developed for gene editing in the mammalian genome (Cong et al., 2013; Gilbert et al., 2014; Jinek et al., 2012; Komor et al., 2017; Mali et al., 2013; Wang et al., 2013), has been used for correcting disease-causing mutations (Huai et al., 2017; Long et al., 2016; Nelson et al., 2016; Park et al., 2015b; Tabebordbar et al., 2016). Similar gene editing





(legend on next page)

approaches have been used to shorten the CGG trinucleotide repeats at the 5' UTR to partially restore *FMR1* expression and normalize the physiological function of FXS patient-derived cells in the dish (Park et al., 2015a; Xie et al., 2016), providing a proof of principle for targeted therapies that involve *FMR1* reactivation. Also, 5-aza-2'-deoxycytidine treatment, inhibition of polycomb repressive complexes, and other molecular interventions for transcriptional regulation have been shown to partially reactivate *FMR1* in patient fibroblast cells (Crunkhorn, 2017; Erickson et al., 2017; Hagerman et al., 2009; Kumari and Usdin, 2016; Tabolacci et al., 2016), suggesting that epigenetic regulation plays a major role for *FMR1* silencing in FXS.

To dissect the functional significance of DNA methylation events in the human genome (Lister et al., 2009, 2013; Schultz et al., 2015), we and others have designed DNA methylation editing tools by fusion of a catalytically inactivated Cas9 with the DNA methylation modification enzymes Dnmt or Tet (dCas9-Dnmt/Tet), allowing targeted modification of DNA methylation in the mammalian genome *in vitro* and *in vivo* (Choudhury et al., 2016; Liu et al., 2016; Vojta et al., 2016; Xu et al., 2016). In the present study, we applied this tool to reverse the hypermethylation of CGG repeats at the *FMR1* locus in multiple FXS patient-derived iPSCs. We designed a single guide RNA (sgRNA) to guide the dCas9-Tet1 to efficiently demethylate the CGG repeats in the pathological *FMR1* locus. Complete demethylation of the CGG expansion induced hypomethylation of the CpG island, increased histone H3 lysine 27 (H3K27) acetylation and H3K4 trimethylation, decreased H3K9 trimethylation at the *FMR1* promoter, and unlocked the epigenetic silencing of the *FMR1* gene, restoring FMRP expression in FXS iPSCs and neurons with no significant off-targeting effect. Expression of *FMR1* and demethylation of its promoter in edited FXS cells were maintained for at least 2 weeks after inhibition of dCas9-Tet1 by a bacteriophage protein, anti-CRISPR type II-A 4 (AcrIIA4). Epigenetic editing rescued the electrophysiological abnormalities of FXS neurons, and the reactivation of *FMR1* was maintained in edited neurons *in vivo* following transplantation into the mouse brain. We also demonstrated that demethylation of the CGG repeats in post-mitotic FXS neurons reactivated *FMR1* and reversed the spontaneous hyperactivity associated with FXS neurons. Our study provides a proof of concept that reversion of gene inactivation by epigenome editing may be a valid therapeutic strategy for disorders that involve epigenetic silencing.

RESULTS

Demethylation of the CGG Repeats to Reactivate *FMR1* in FXS iPSCs

To test whether demethylation of the hypermethylated CGG repeats can reactivate *FMR1*, we infected FX52 iPSCs, a previously described FXS iPSC line (Urbach et al., 2010) containing about 450 CGG repeats in the 5' UTR of *FMR1*, with lentiviruses expressing dCas9-Tet1(dC-T)-P2A-tag blue fluorescent protein (tBFP) and an mCherry-expressing sgRNA targeting the "GGCG GCGGCGGCGGCGGCGGNGG" sequence (CGG sgRNA), and collected cells expressing both vectors by fluorescence-activated cell sorting (FACS) (Figure 1A). As shown in Figure 1B, the expression level of *FMR1* mRNA in cells with dC-T/CGG sgRNA was restored to 90% of the one in wild-type WIBR1 human embryonic stem cells (hESCs), whereas cells expressing a catalytically dead Tet1 (dC-dT) and the same sgRNA did not reactivate *FMR1*. Further, FMRP expression was restored in dC-T/CGG sgRNA-expressing FX52 iPSCs to 73% of the wild-type level in WIBR1 cells, as shown by immunofluorescence staining and western blotting (Figures 1C and 1D). Methylation analysis of the CGG repeats showed a significant reduction of methylation from 100% in mock FX52 iPSCs to 4% in dC-T/CGG sgRNA-expressing FX52 iPSCs (Figure 1E), and bisulfite sequencing (BS-seq) of the *FMR1* promoter showed a robust demethylation after infection with lentiviral dC-T/CGG sgRNA vectors (Figures 1F and 1G). These data indicate that dCas9-Tet1 targeted by the CGG sgRNA can efficiently demethylate the CGG repeats in FX52 iPSCs, resulting in subsequent demethylation of the *FMR1* promoter and reactivation of *FMR1* both on the transcriptional and translational levels. Two additional FXS iPSC lines with more than 450 CGG trinucleotide repeats (Brick et al., 2014; Xie et al., 2016) were also used to test the reactivation of *FMR1* by dCas9-Tet1/CGG sgRNA. As shown in Figures S1A and S1B, *FMR1* was reactivated after lentiviral transduction of dCas9-Tet1 and CGG sgRNA in both cell lines. *FMR1* was reactivated to ~60% and ~30% of the level seen in WIBR1 wild-type cells, respectively. The different levels of *FMR1* expression are likely due to variable vector expressions in these particular experiments (see analysis in Figure 2A). We conclude that targeted demethylation of the CGG repeat expansion by dCas9-Tet1/CGG sgRNA can reactivate *FMR1* in multiple FXS patient-derived iPSCs. The FX52 iPSC line was used for further studies.

Figure 1. Reactivation of *FMR1* by dCas9-Tet1 in FXS iPSCs

- (A) Schematic representation of targeting the CGG repeats of *FMR1* by dCas9-Tet1 with a CGG sgRNA to erase methylation and activate *FMR1* expression.
 (B) A previously reported FXS iPSC line (FX52) was infected with lentiviruses expressing dCas9-Tet1-P2A-BFP (dC-T) with an mCherry-expressing sgRNA targeting the CGG repeats GGCGGCGGCGGCGGCGGNGG (CGG sgRNA) or lentiviruses expressing dCas9 fused with a catalytically dead Tet1 (dC-dT) with the same sgRNA. Double positive (BFP+; mCherry+) cells were isolated by FACS after infection. The expression level of *FMR1* was quantified by qPCR analysis and is shown as the mean of relative percentages to the one in WIBR1 hESCs \pm SD of three biological replicates.
 (C) The cells in (B) were cultured on feeder mouse embryonic fibroblasts (MEFs) and subject to immunofluorescence staining. Scale bar, 100 μ m. Cells are stained green for FMRP, red for Cas9, and blue for DNA.
 (D) The cells in (B) were subjected to western blot analysis. The protein level of FMRP was quantified by ImageJ and is shown as the mean of relative percentages to the one in WIBR1 hESCs \pm SD of two biological replicates.
 (E) Methylation levels of the CGG repeats in the *FMR1* locus. Shown is the mean percentage of two biological replicates.
 (F) BS-seq of the cells described in (B).
 (G) Methylation levels of individual CpGs in the *FMR1* promoter region. Shown is the mean percentage \pm SD of two biological replicates.

See also Figure S1.




Figure 2. Off-Target Effects of dCas9-Tet1/CGG sgRNA

(A) qRT-PCR analysis of three FX52 iPSC lines with different expression levels of dCas9-Tet1 and different restoration levels of *FMR1* normalized to wild-type WIBR1 hESCs.

(B) A Manhattan plot depicting genome-wide binding sites of dCas9-Tet1/CGG sgRNA identified in the cells described in (A). All peaks with $p < 10^{-15}$ are shown.

(C) BS-seq and pyrosequencing (Pyro-seq) of the 6 top off-target candidate gene loci that overlapped with methylated promoter regions according to a hESC/iPSC methylome study reported previously (Lister et al., 2009) and showed the highest binding affinity of dCas9-Tet1 in (B). The CGG sgRNA target site (GGCGGCGGCGGCGGCGGCGG) is illustrated with a red hexagon. The mismatch target site is illustrated with a yellow dot. CpGs are indicated by vertical bars. Shown is the mean percentage \pm SD of two biological replicates.

(D) Gene expression analyses of the 6 top off-target candidate genes by qPCR. Shown is the mean percentage \pm SD of two biological replicates.

(E) Anti-Cas9 ChIP-BS-seq of FX52 iPSCs expressing dCas9-Tet1/CGG sgRNA (line 1 in A) or dCas9-dTet1/CGG sgRNA. 28 binding sites with a change of methylation larger than 10% are labeled in red; *FMR1* is labeled in green. The diameter of a circle is in proportion to the number of CGG sgRNA target sites; binding sites with mismatched target site are indicated by the smallest circles. Blue lines of circles indicate binding sites overlapping with a promoter region. The dashed lines mark the 10% methylation difference between samples.

(F) RNA-seq of the mock and dCas9-Tet1/CGG sgRNA-expressing FX52 iPSC line 1 described in (A). Red dots highlight the 28 genes with a change of methylation larger than 10% identified in (E). *FMR1* is labeled with a green dot. The dashed red lines mark the 4-fold difference between the samples.

See also Figure S1.

The Off-Target Effect of dCas9-Tet1 Is Minimal

The presence of the CGG sgRNA targeting sequence GGC GGCGGCGGCGGCGGCGGNGG in other genomic loci raises concerns regarding off-target effects of the dCas9-Tet1/sgRNA system used. We examined the genome-wide binding sites for dCas9-Tet1 with CGG sgRNA by an anti-Cas9 chromatin immunoprecipitation sequencing (ChIP-seq) experiment using three FX52 iPSC lines expressing different levels of dCas9-Tet1 generated by lentiviral transduction with different viral titers. We observed that the restoration level of *FMR1* decreased from 90% to 20% when the expression level of dCas9-Tet1 was reduced from 100% to 21% (Figure 2A), whereas reduction of CGG sgRNA did not affect the level of *FMR1* reactivation (Figure S1C), suggesting that dCas9-Tet1 rather than sgRNA was the limiting factor. The number of genome-wide dCas9-Tet1 binding sites was also decreased when the expression level of dCas9-Tet1 was reduced (Figure 2B). To examine possible off-target effects in more detail, we chose FX52 iPSC line 1 for further analysis because it has the highest number of dCas9-Tet1 binding sites among the three lines in which 90% of the *FMR1* mRNA level was restored (Figure 2A). Among these binding sites, we first analyzed the top 6 candidate loci overlapping with methylated promoter regions according to a hESC/iPSC methylome study reported previously (Lister et al., 2009) and showing the highest binding affinity of dCas9-Tet1 in ChIP-seq (Figure 2B). BS-seq showed a 20% and 30% reduction of methylation levels for *SHCBP1L* with one CGG sgRNA targeting site and *RGPD1* with 6 targeting sites, respectively, but no detectable methylation changes for the other four genes (Figure 2C). The level of demethylation in *SHCBP1L* and *RGPD1* loci likely correlates with the number of dCas9-Tet1/CGG sgRNA targeting sites. Gene expression analysis by qPCR showed either undetectable or minor changes with a 2.2-fold upregulation of *SHCBP1L* as the highest level of change (Figure 2D). To evaluate the methylation editing at a genome-wide level, we performed an anti-Cas9 ChIP-BS-seq experiment using FX52 iPSCs expressing dCas9-Tet1/CGG sgRNA (line 1 in Figure 2A) or dCas9-dTet1/CGG sgRNA. The result of this experiment allowed comparison of methylation levels at 1,018 dCas9-Tet1 binding sites between these two lines (Figure 2E). 29 loci showed a change of methylation larger than 10%, with the *FMR1* locus displaying the most significant methylation decrease (85%) in edited cells. Importantly, RNA sequencing (RNA-seq) analysis of mock- and methylation-edited FX52 cells showed no significant change in overall gene expression (a correlation coefficient of 0.99; Figure 2F). In contrast to the 1,500-fold upregulation of *FMR1* expression, either no change or a minor change (maximal 4-fold) of expression was detected for the 28 genes with a change of methylation larger than 10% identified by ChIP-BS-seq. These data suggest that the off-target effect of dCas9-Tet1/CGG sgRNA on the DNA methylation and transcription levels is minimal and could be further minimized by titration of the expression level of dCas9-Tet1.

Activation of the Heterochromatic *FMR1* Promoter

As shown previously, the *FMR1* promoter region in FXS patient cells is in a heterochromatic conformation with DNA

hypermethylation, decreased histone acetylation and H3K4 trimethylation, and increased histone H3K9 trimethylation (Coffee et al., 1999, 2002). To dissect the molecular mechanism of *FMR1* reactivation by dCas9-Tet1/CGG sgRNA-mediated demethylation of the CGG repeats, we examined the epigenetic state of the *FMR1* promoter by ChIP-seq assays with antibodies against RNA polymerase II (Pol II), histone H3 lysine 4 trimethylation (H3K4me3), histone H3 lysine 27 acetylation (H3K27Ac), H3K27me3, and H3K9me3. As shown in Figure 3A, Pol II was recruited to the *FMR1* promoter in the methylation-edited cells but not in the cells expressing dCas9-dTet1/CGG sgRNA. The active chromatin marks H3K4me3 and H3K27Ac were localized to the promoter regions in the edited cells, with the repressive marker H3K9me3 being reduced, suggesting a switch of the heterochromatin state of the *FMR1* promoter to an active chromatin conformation after demethylation of the CGG repeats. Two control loci, including *POU5F1* and *MYOD1*, showed no detectable change for these marks in edited cells. Genome-wide analysis of Pol II occupancy showed that *FMR1* is the most upregulated gene in the edited cells, whereas the 28 genes with a change of methylation of larger than 10% showed either no change or a minor change of Pol II occupancy (less than 3-fold), except *GSE1* with a 5-fold change (Figure 3B). Nevertheless, the expression level of *GSE1* did not change in the edited cells (Table S3). These data confirm a selective activation of *FMR1* by dCas9-Tet1/CGG sgRNA. Genome-wide analysis of histone H3K4me3 distribution again highlighted the effect at the *FMR1* locus with either no change or a minor change (less than 3-fold) for all 28 genes (Figure 3C). Our observations support the role of DNA methylation of the CGG repeats as the major epigenetic block in silencing of *FMR1* and argue that demethylation of these repeats is sufficient to rebuild an active chromatin status for the *FMR1* promoter, allowing its reactivation.

Kinetics and Persistence of *FMR1* Reactivation

To gain insight into the kinetics of *FMR1* reactivation by methylation editing, we performed a time course experiment to monitor the expression of *FMR1*. As shown in Figure 4A, the expression of *FMR1* was first detected at the 9-day time point after infection with dCas9-Tet1/CGG sgRNA lentiviruses and peaked around 3 weeks, accompanied by demethylation of the *FMR1* promoter (Figure 4D). To examine the persistence of methylation editing, we used AcrIIA4, a previously described inhibitor of Cas9/dCas9 (Rauch et al., 2017), to inactivate dCas9-Tet1. Expression of AcrIIA4 blocked the binding of dCas9-Tet1 to the *FMR1* locus, as shown in Figure 4B. We observed that *FMR1* expression and demethylation of its promoter were maintained in the presence of AcrIIA4 for at least 2 weeks (Figures 4C and 4D), suggesting that constitutive presence of dCas9-Tet1 at the CGG repeats may not be required to sustain *FMR1* reactivation through cell division.

Rescue of the FXS Phenotype in Edited Neurons

To evaluate the effect of *FMR1* reactivation on the rescue of FXS-related cellular phenotypes, post-mitotic neurons were




Figure 3. Chromatin Conformation of the Reactivated *FMR1* Promoter

(A) Anti-RNA polymerase II (Pol II, referred to as RNAPII), anti-histone H3K4me3, anti-H3K27Ac, anti-H3K27me, and anti-H3K9me3 ChIP-seq signals at the *FMR1*, *POU5F1*, and *MYOD1* loci in mock and edited FX52 iPSCs.

(B and C) Genome-wide Pol II occupancy (B) and histone H3K4me3 occupancy (C) of mock and edited FX52 iPSCs. Red dots highlight the 28 genes associated with a change of methylation larger than 10%, as described in Figure 2E. *FMR1* is labeled with a green dot. Promoters with a 3-fold or more change in factor occupancy are plotted as blue circles.

expressing dC-T/CGG sgRNA or dC-dT/CGG sgRNA allowed comparison of methylation levels at 670 binding sites and identified 43 sites with a change of methylation larger than 10%, including a 38% decrease of methylation at the *FMR1* locus (Table S2). Nevertheless, transcriptome analysis of FX52 mock neurons and edited neurons outlined *FMR1* as the most upregulated gene (481-fold) and showed either no change or a minor change (4-fold) of expression for the 41 genes and a 9-fold change for the *RGPD1* gene associated with a larger than 10% methylation change, highlighted with red dots in Figure 5E, suggesting a specific reactivation of *FMR1*. To examine the electrophysiological properties of methylation-edited FXS neurons, a multi-electrode array (MEA) assay was performed with wild-type WIBR1 neurons and FX52 mock-, dC-T/CGG sgRNA-, and dC-dT/CGG sgRNA-expressing neurons. As shown in Figure 5F, the significantly higher firing rate of FX52 neurons was reduced to the levels of wild-type neurons in dC-T/CGG sgRNA-expressing neurons but not in neurons expressing dC-dT/CGG

sgRNA. These results suggest that reactivation of *FMR1* reversed the spontaneous hyperactive phenotype of FXS neurons.

derived from the methylation-edited FX52 iPSCs, as shown in Figure 5A, with a well-established differentiation protocol (Chambers et al., 2009). Gene expression analysis of lineage-specific markers suggested comparable differentiation states between wild-type and mutant neural cultures (Figure 5B). The expression level of *FMR1* in neurons expressing dC-T/CGG sgRNA was 82% of the one in wild-type neurons, and *FMR1* remained silent in the neurons expressing dC-dT/CGG sgRNA (Figure 5C), suggesting that differentiation of edited FXS iPSCs did not affect *FMR1* reactivation. Immunohistochemistry confirmed that FMRP remained expressed in the edited neurons (Figure 5D). Genome-wide methylation analysis by ChIP-BS-seq using neurons derived from FX52 iPSCs

sgRNA. These results suggest that reactivation of *FMR1* reversed the spontaneous hyperactive phenotype of FXS neurons.

***FMR1* Reactivation in Edited FXS Neurons Is Sustained after Engrafting into Mouse Brains**

To test whether the reactivation of *FMR1* in methylation-edited FXS cells is sustainable *in vivo*, FX52 mock- or methylation-edited neuronal precursor cells (NPCs) were labeled with GFP or red fluorescent protein (RFP) lentiviruses, respectively, and then the mixture of these two types of NPCs was injected into the P1 mouse brain for subsequent analysis 1 or 3 months after transplantation (Figure 5G). Immunofluorescence staining of the




Figure 4. The Kinetics and Persistence of Methylation Editing

(A) FX52 iPSCs were infected with lentiviruses expressing dC-T and a CGG sgRNA and harvested for qPCR analysis of *FMR1* expression at various time points. Shown is the mean expression level relative to that in a CGG deletion FX52 iPSC line (\pm SD of two biological replicates). This CGG deletion FX52 iPSC line was previously reported to restore *FMR1* expression (Park et al., 2015a).

(B) 293T cells were transfected with dC-T alone, with dC-T/CGG sgRNA, or with dC-T/CGG sgRNA and AcrIIA4. The cells were subject to an anti-Cas9 ChIP experiment, and the enrichment of dC-T at the *FMR1* and *BDNF* loci was examined by qPCR analysis. Shown is the mean of relative binding normalized to the input \pm SD from three biological replicates.

(C) Cells on day 23 (labeled as Meth-edited) in (A) were infected with a lentivirus expressing AcrIIA4 and harvested for qPCR analysis at various time points. Shown are the mean *FMR1* (red bar) and AcrIIA4 (blue bar) expression levels relative to the levels in the CGG deletion FX52 iPSC line (CGGΔ) and the cells on day 3 after AcrIIA4 infection, respectively (\pm SD of two biological replicates).

(D) Pyro-seq of the cells in (A) and (C). Shown is the mean percentage \pm SD of two biological replicates.

mouse brain sections showed that 56% and 57% of the edited FX52 neurons (RFP-positive) in 1- and 3-month post-transplanted mice, respectively, expressed FMRP, whereas FX52 mock neurons (GFP-positive) were negative for FMRP expression (Figure 5H), suggesting that *FMR1* reactivation can be maintained *in vivo* after transplantation.


Deletion of CGG Repeats Results in a Similar Phenotypic Rescue as Epigenetic Editing

To evaluate the rescue effects observed in methylation-edited FXS cells compared with cells lacking the CGG expansion mutation, we characterized a pair of FXS iPSC lines, including an isogenic line with CGG deletion, by CRISPR/Cas9 technology (Xie et al., 2016). Both *FMR1* mRNA and FMRP were restored in the CGG deletion line (Figures 6A–6C). The methylation level of the *FMR1* promoter was reduced to 39% in the CGG deletion

line (Figures 6D and 6E). Importantly, the spontaneous hyperactivity associated with FXS neurons was significantly reduced in CGG deletion FXS neurons, as shown in Figures 6F and 6G. Thus, the decrease of *FMR1* promoter methylation and the reversal of hyperactivity in CGG deletion FXS cells are consistent with our observations in methylation-edited FXS cells, suggesting a functional rescue of FXS-related cellular phenotypes by demethylation of the CGG expansion.

Direct Reactivation of *FMR1* in FXS Neurons

Because neurons are the most disease-relevant cell type in FXS patients, we tested whether *FMR1* could be reactivated with dCas9-Tet1/CGG sgRNA in post-mitotic neurons derived from FXS iPSCs. After infection with lentiviruses expressing dC-T or dC-dT with CGG sgRNA, the mRNA level of *FMR1* in dC-T/CGG sgRNA-expressing FXS neurons was restored to 45% of



(legend on next page)

the one in wild-type neurons, but dC-dT/CGG sgRNA did not reactivate *FMR1* (Figure 7B). FMRP proteins were only detected in neurons expressing dC-T/CGG sgRNA but not dC-dT/CGG sgRNA (Figure 7A). These results suggest that reactivation of *FMR1* in post-mitotic FXS neurons is achievable by dCas9-Tet1/CGG sgRNA but less efficiently compared with FXS iPSCs (Figures 1B and 1C). Analysis of the CGG methylation status showed a 30% reduction in the edited neurons compared with FXS mock neurons (Figure 7C). BS-seq of the *FMR1* promoter in these neurons showed a 20% decrease of the methylation level in the edited FXS neurons compared with FXS mock neurons (Figure 7D). The demethylation of the CGG repeats and subsequent demethylation of the *FMR1* promoter and the reactivation of the *FMR1* gene were less robust compared with that seen in edited iPSCs (Figure 1). This is likely due to our inability to isolate double vector-infected neurons by FACS and the different DNA demethylation mechanism in post-mitotic neurons compared with dividing iPSCs (Wu and Zhang, 2014). Nevertheless, MEA assays revealed a rescue of the electrophysiological abnormalities in the edited FXS neurons (Figure 7E), suggesting that the spontaneous hyperactivity associated with FXS neurons was reversed after reactivation of *FMR1* in these neurons.

DISCUSSION

In this study, we applied recently developed DNA methylation editing tools to reverse hypermethylation of the CGG repeats in the *FMR1* locus. An iPSC-based FXS model was chosen because it recapitulates the hypermethylation of CGG repeat expansion and epigenetic silencing of *FMR1*. Our results demonstrate that targeted demethylation of the CGG repeats reactivated *FMR1* in multiple FXS iPSCs as well as in *in vitro*-derived FXS neurons. Demethylation of the CGG repeats resulted in conversion of the heterochromatic state to an active state of the non-targeted upstream *FMR1* promoter. Thus, our data provide the first direct evidence that demethylation of the CGG repeats is sufficient to reactivate *FMR1*. Importantly, methylation editing reversed the abnormal electrophysiological phenotype of FXS neurons, and the expression of FMRP in

edited neurons was maintained *in vivo* after transplantation into the mouse brain. To address potential off-target effects associated with the dCas9-Tet1/CGG sgRNA system, we performed a genome-wide survey to identify binding sites of dCas9-Tet1 with CGG sgRNA and examined the methylation levels of these sites. ChIP-BS-seq revealed a small set of sites with changes in methylation larger than 10%, and RNA-seq analysis showed no major off-target effects on transcriptional levels of these genes, suggesting a highly specific effect by targeted methylation editing.

Trinucleotide repeat expansions play a pathological role in several neurological, neurodegenerative, and neuromuscular disorders such as FXS, Huntington's disease, spinocerebellar ataxia, and myotonic dystrophy (Nelson et al., 2013; Pearson et al., 2005). Repeats can elicit toxicity through a series of overlapping pathogenic cascades, including gain of function or loss of function at the protein and/or RNA level(s). Silencing of *FMR1* with more than 200 CGG repeats is considered the cause for FXS. However, carrier patients with 55–200 CGG repeats have overproduction of *FMR1* mRNA but reduction of FMRP protein and develop fragile X-associated tremor and ataxia syndrome (FXTAS) with some features of the FXS phenotype, including progressive cerebellar tremor and ataxia, cognitive impairment, mild parkinsonian symptoms, and brain atrophy (Hagerman et al., 2001). The repeat-associated non-adenosine uridine guanosine (AUG) (RAN) translation of a transfected CGG repeat-containing construct has been shown to generate toxic neuronal proteins (Kearse et al., 2016; Todd et al., 2013). Also, RNA inclusions were found in a small subgroup (6%–11%) of FXTAS nuclei (Tassone et al., 2004; Wojciechowska and Krzyzosiak, 2011). Restoration of FMRP protein and rescue of FXS cellular phenotypes after reactivation of *FMR1* argue that the cellular toxicity assumed for CGG repeat-containing *FMR1* RNA is likely to be minimal in methylation-edited FXS cells within a short period of culture time. It remains an open question whether the reactivated *FMR1* in FXS cells results in RAN and/or forms intranuclear RNA inclusions, but our tool provides a unique experimental system to further investigate the toxicity of CGG repeats in neurons.

Figure 5. Phenotypical Rescue of FXS-Related Cellular Deficits

- (A) Methylation-edited FX52 iPSCs were differentiated into neuronal processor cells (NPCs) and post-mitotic neurons. Scale bar, 500 μ m.
- (B) Expression levels of lineage-specific markers in neurons described in (A) measured by qPCR. Shown is the mean percentage \pm SD of two biological replicates.
- (C) *FMR1* expression level of neurons in (A) measured by qPCR. Shown is the mean percentage \pm SD of two biological replicates.
- (D) The neurons in (A) were subjected to immunofluorescence staining. Scale bar, 100 μ m. Neurons were stained green for FMRP, red for Cas9, blue for DNA, and gray for MAP2.
- (E) RNA-seq of mock and dCas9-Tet1/CGG sgRNA expressing the FX52 neurons described in (A). Red circles highlight 43 genes with a change of methylation larger than 10% in dCas9-Tet1/CGG sgRNA-expressing neurons (Table S2). *FMR1* is labeled with a green dot. The dashed red lines mark a 4-fold difference between the samples.
- (F) Multi-electrode array (MEA) of wild-type WIBR1 neurons and FX52 mock, dCas9-Tet1/CGG sgRNA-, or dCas9-dTet1/CGG sgRNA-expressing neurons. Shown is the mean \pm SD of biological triplicates for each type of neurons.
- (G) Schematic representation of engraftment of 1:1 mixed cells containing mock FX52 NPCs labeled with GFP and methylation-edited FX52 NPCs labeled with RFP into the post-natal day 1 (P1) mouse brain and harvested for analysis 1 month post-engraftment.
- (H) Representative confocal micrographs of cells engrafted in the mouse brain 1 month post-transplantation. Scale bar, 50 μ m. Cells were stained red for RFP, green for GFP, magenta for FMRP, and blue for DNA. A total of 496 RFP-positive neurons and 149 GFP-positive neurons from three mice after 1 month were counted. 56% \pm 9% of RFP neurons were FMRP-positive, whereas all GFP-positive neurons were FMRP-negative. A total of 203 RFP-positive neurons and 117 GFP-positive neurons from two mice after 3 months were counted. 57% \pm 3% of RFP neurons were FMRP-positive, whereas all GFP positive neurons were FMRP-negative.




Figure 6. Deletion of CGG Repeats to Rescue FXS Phenotypes

(A) Schematic representation of deletion of the CGG repeats in the *FMR1* locus by CRISPR/Cas9 to activate *FMR1* expression.

(B) *FMR1* mRNA level measured by qRT-PCR in a control iPSC line, an FXS iPSC line with more than 450 CGG repeats, and a CGG deletion FXS iPSC line generated by CRISPR/Cas9 gene editing (Xie et al., 2016). Shown is the mean \pm SD of 3 biological replicates.

(C) FMRP expression in neurons derived from the iPSCs in (B). Neurons were stained blue for DAPI, green for MAP2, and red for FMRP. Scale bar, 100 μ m.

(D) Summary of the methylation levels of the CGG repeats and the *FMR1* promoter for the cells in (B). (E) Methylation levels of CpGs in the *FMR1* promoter of the cells in (B).

(F) MEA assay of the neurons derived from the iPSCs in (B) with the Ngn2 method (Zhang et al., 2013). Shown is the mean \pm SD of 6 biological replicates.

(G) Quantification of the neural firing rate 22 days after plating on the MEA plate. Shown is the mean \pm SD of 6 biological replicates.

specificity and efficiency of dCas9-Tet1/CGG sgRNA are likely due to the repetitive nature of the CGG repeats present in the *FMR1* locus in FXS cells, which allows for enrichment of the dCas9-Tet1 machinery on the condensed CGG repeats for efficient methylation editing. Importantly, RNA-seq revealed either no change or minor changes of expression for the genes associated with these sites, suggesting a highly specific effect on *FMR1* reactivation by methylation editing. Nevertheless, off-target binding of dCas9-Tet1 is a concern. We found that the level of dCas9-Tet1 vector expression was positively correlated with both the expression level of *FMR1* and the number of off-target binding sites of dCas9-Tet1, suggesting that the dCas9-Tet1/CGG sgRNA is a tunable methylation editing

Accurate and efficient targeting with a controllable off-target effect is the ultimate goal for gene therapy and epigenome editing toward therapeutic intervention. To examine the potential off-target effect of dCas9-Tet1/CGG sgRNA, we performed a series of genome-wide analyses of methylation-edited FXS cells. Compared with the robust reduction in methylation of the *FMR1* locus (84% decrease), a global methylation analysis of FXS cells expressing dCas9-Tet1/CGG sgRNA or dCas9-Tet1/CGG sgRNA by ChIP-BS-seq revealed that only a small set of binding loci (28 of 1,018 sites in edited FXS iPSCs and 42 of 670 sites in edited FXS neurons) changed the level of methylation by more than 10%. The high methylation editing

tool that allows restoration of *FMR1* at different expression levels, with a potentially controllable off-target effect to safely rescue FXS phenotypes. Furthermore, we observed that reactivation of *FMR1* and demethylation of its promoter did not require constitutive editing by dCas9-Tet1 and was maintained for at least 2 weeks after inactivation of dCas9-Tet1. Another strategy to minimize off-target binding would be to target the dCas9-Tet1 to the *FMR1* promoter instead of the CGG repeats because targeting the promoter would allow for designing unique sgRNAs and reducing potential off-target binding of dCas9-Tet1.

Whether the FXS phenotype can be reversed postnatally is unknown. It has been shown that re-expression of FMRP by




Figure 7. Direct Reactivation of FMR1 in FXS Neurons

(A) FX52 neurons were infected with lentiviruses expressing dC-T and the CGG sgRNA or dCas9-dTet1 (dC-dT) with the same sgRNA. Infected neurons were subject to immunofluorescence staining. Scale bar, 50 μ m. Neurons were stained green for FMRP, red for Cas9, blue for DNA, and gray for MAP2.

(B) The expression level of FMR1 in (A) was quantified by qPCR analysis and is shown as the mean relative to the level in WIBR1 hESCs \pm SD of two biological replicates.

(C) Methylation levels of the CGG repeats in the FMR1 locus. Shown is the mean percentage \pm SD of two biological replicates.

(D) BS-seq of the FMR1 promoter in the cells described in (A). Shown is the mean percentage \pm SD of two biological replicates.

(E) MEA assay of the neurons in (A). Shown is the mean percentage \pm SD of two biological replicates.

AAV-based gene delivery could partially rescue the neuronal phenotype in *Fmr1* mutant mice, suggesting that the functional deficits may be at least partially reversible (Gholizadeh et al., 2014; Zeier et al., 2009). We have demonstrated that restoration of FMR1 can be achieved in *in vitro*-derived FXS neurons by dCas9-Tet1/CGG sgRNA-mediated methylation editing. Electrophysiological analysis of the edited neurons with 45% restoration of FMR1 showed a similar behavior as wild-type neurons, indicating that the FXS cellular phenotype is likely reversible in neurons and that full restoration of FMR1 may not be necessary

for a functional rescue, opening a potential therapeutic window for the treatment of FXS.

In summary, our study demonstrates that demethylation of the CGG repeats is sufficient to reactivate FMR1. Thus, methylation editing is a valid strategy to reactivate FMR1 and to rescue the FXS-related cellular phenotypes, providing a proof-of-concept paradigm to study disease-associated abnormal DNA methylation events. This method for epigenome editing can be easily applied to examine the causality of disease-associated DNA methylation events and evaluate the consequences after

targeted reversal of the DNA methylation status, holding great potential for future research of novel therapies.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- [KEY RESOURCES TABLE](#)
- [CONTACT FOR REAGENT AND RESOURCE SHARING](#)
- [EXPERIMENTAL MODEL AND SUBJECT DETAILS](#)
 - Mouse lines and breeding strategies
- [METHOD DETAILS](#)
 - Plasmid design and construction
 - Cell culture and lentivirus production
 - Multi-electrode array recording
 - Transplantation of FXS NPCs into mouse brain
 - Immunocytochemistry, immunohistochemistry, microscopy, and image analysis
 - FACS analysis
 - Western blot
 - RT-qPCR
 - Chromatin Immunoprecipitation
 - Cas9 ChIP-seq peak calling method
 - ChIP-seq Scatterplot method
 - ChIP-BS-seq
 - Bisulfite Conversion, PCR and Sequencing
 - DNA Methylation analysis
 - RNA-seq and analysis
- [QUANTIFICATION AND STATISTICAL ANALYSIS](#)
- [DATA AND SOFTWARE AVAILABILITY](#)

SUPPLEMENTAL INFORMATION

Supplemental Information includes one figure and six tables and can be found with this article online at <https://doi.org/10.1016/j.cell.2018.01.012>.

ACKNOWLEDGMENTS

We thank Patti Wisniewski, Patrick Autissier, and Hanna Aharonov for FACS and Maisam Mitalipova, Dongdong Fu, Robert Plasschaert, Malkiel Cohen, Carrie Ng, and Vivian Villegas for reagents, technical assistance, and input on the manuscript. We thank Steve Warren at Emory University for providing FXS_SW isogenic iPSC lines. This study was supported by NIH grants HD045022, MH104610, R01NS088538, and R01GM123511. X.S.L. is supported by a Damon Runyon Cancer Foundation postdoctoral fellowship and funding from the Rett Syndrome Research Trust. H.W. was supported by a NARSAD Young Investigator Fellowship. X.W. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship.

AUTHOR CONTRIBUTIONS

X.S.L. and R.J. conceived the idea for this project. X.S.L., H.W., and R.J. designed the experiments and interpreted the data. X.S.L. performed the experiments. M.K. performed the transplantation experiment in mouse brains. X.W. and B.Y. assisted with the sequencing analysis. C.X. assisted with BS-seq. J.M. and Y.L. assisted with the MEA assay and data analysis. D.H. and C.H.L. performed Pol II, H3K4me3, H3K27Ac, H3K9me3, and H3K27me ChIP-seq experiments and, with R.A.Y., the analysis of these data. H.W. and J.G. characterized the CGG deletion FXS isogenic line and, with A.C., the analysis of this data. D.V. provided the FXS2 iPSCs. X.S.L., H.W., and R.J. wrote the manuscript with input from all the other authors.

DECLARATION OF INTERESTS

R.J. is a co-founder of Fate Therapeutics, Fulcrum Therapeutics, and Omega Therapeutics. R.A.Y. is a co-founder of Syros Pharmaceuticals, Marauder Therapeutics, and Omega Therapeutics.

Received: August 31, 2017

Revised: December 6, 2017

Accepted: January 7, 2018

Published: February 15, 2018

REFERENCES

- Avitzour, M., Mor-Shaked, H., Yanovsky-Dagan, S., Aharoni, S., Altarescu, G., Renbaum, P., Eldar-Geva, T., Schonberger, O., Levy-Lahad, E., Epsztejn-Litman, S., and Eiges, R. (2014). FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells. *Stem Cell Reports* 3, 699–706.
- Berman, R.F., Buijssen, R.A., Usdin, K., Pintado, E., Kooy, F., Pretto, D., Pesah, I.N., Nelson, D.L., Zalewski, Z., Charlet-Bergeurand, N., et al. (2014). Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome. *J. Neurodev. Disord.* 6, 25.
- Bernardet, M., and Crusio, W.E. (2006). Fmr1 KO mice as a possible model of autistic features. *Sci. World J.* 6, 1164–1176.
- Brick, D.J., Nethercott, H.E., Montesano, S., Banuelos, M.G., Stover, A.E., Schutte, S.S., O'Dowd, D.K., Hagerman, R.J., Ono, M., Hessel, D.R., et al. (2014). The autism spectrum disorders stem cell resource at Children's Hospital of Orange County: implications for disease modeling and drug discovery. *Stem Cells Transl. Med.* 3, 1275–1286.
- Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* 27, 275–280.
- Choudhury, S.R., Cui, Y., Lubecka, K., Stefanska, B., and Irudayaraj, J. (2016). CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. *Oncotarget* 7, 46545–46556.
- Coffee, B., Zhang, F., Warren, S.T., and Reines, D. (1999). Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. *Nat. Genet.* 22, 98–101.
- Coffee, B., Zhang, F., Ceman, S., Warren, S.T., and Reines, D. (2002). Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile X syndrome. *Am. J. Hum. Genet.* 71, 923–932.
- Colak, D., Zaninovic, N., Cohen, M.S., Rosenwaks, Z., Yang, W.Y., Gerhardt, J., Disney, M.D., and Jaffrey, S.R. (2014). Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. *Science* 343, 1002–1005.
- Comery, T.A., Harris, J.B., Willems, P.J., Oostra, B.A., Irwin, S.A., Weiler, I.J., and Greenough, W.T. (1997). Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. *Proc. Natl. Acad. Sci. USA* 94, 5401–5404.
- Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823.
- Contractor, A., Klyachko, V.A., and Portera-Cailliau, C. (2015). Altered neuronal and circuit excitability in fragile X syndrome. *Neuron* 87, 699–715.
- Crunkhorn, S. (2017). Genetic disorders: repurposing metformin in FXS. *Nat. Rev. Drug Discov.* 16, 456.
- Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 146, 247–261.
- de Esch, C.E., Ghazvini, M., Loos, F., Schelling-Kazaryan, N., Widagdo, W., Munshi, S.T., van der Wal, E., Douben, H., Gunhanlar, N., Kushner, S.A., et al. (2014). Epigenetic characterization of the FMR1 promoter in induced

- pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation. *Stem Cell Reports* 3, 548–555.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dolan, B.M., Duron, S.G., Campbell, D.A., Vollrath, B., Shankaranarayana Rao, B.S., Ko, H.Y., Lin, G.G., Govindarajan, A., Choi, S.Y., and Tonegawa, S. (2013). Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. *Proc. Natl. Acad. Sci. USA* 110, 5671–5676.
- Dölen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., and Bear, M.F. (2007). Correction of fragile X syndrome in mice. *Neuron* 56, 955–962.
- Eiges, R., Urbach, A., Malcov, M., Frumkin, T., Schwartz, T., Amit, A., Yaron, Y., Eden, A., Yanuka, O., Benvenisty, N., and Ben-Yosef, D. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. *Cell Stem Cell* 1, 568–577.
- Erickson, C.A., Davenport, M.H., Schaefer, T.L., Wink, L.K., Pedapati, E.V., Sweeney, J.A., Fitzpatrick, S.E., Brown, W.T., Budimirovic, D., Hagerman, R.J., et al. (2017). Fragile X targeted pharmacotherapy: lessons learned and future directions. *J. Neurodev. Disord.* 9, 7.
- Gholizadeh, S., Arsenault, J., Xuan, I.C., Pacey, L.K., and Hampson, D.R. (2014). Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. *Neuropsychopharmacology* 39, 3100–3111.
- Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., et al. (2014). Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* 159, 647–661.
- Hagerman, R.J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., and Hagerman, P.J. (2001). Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. *Neurology* 57, 127–130.
- Hagerman, R.J., Berry-Kravis, E., Kaufmann, W.E., Ono, M.Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessler, D., Visootsak, J., et al. (2009). Advances in the treatment of fragile X syndrome. *Pediatrics* 123, 378–390.
- Halevy, T., Czech, C., and Benvenisty, N. (2015). Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. *Stem Cell Reports* 4, 37–46.
- Hayashi, M.L., Rao, B.S., Seo, J.S., Choi, H.S., Dolan, B.M., Choi, S.Y., Chattarji, S., and Tonegawa, S. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. *Proc. Natl. Acad. Sci. USA* 104, 11489–11494.
- Huai, C., Jia, C., Sun, R., Xu, P., Min, T., Wang, Q., Zheng, C., Chen, H., and Lu, D. (2017). CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. *Hum. Genet.* 136, 875–883.
- Huber, K.M., Gallagher, S.M., Warren, S.T., and Bear, M.F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc. Natl. Acad. Sci. USA* 99, 7746–7750.
- Irwin, S.A., Galvez, R., and Greenough, W.T. (2000). Dendritic spine structural anomalies in fragile-X mental retardation syndrome. *Cereb. Cortex* 10, 1038–1044.
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337, 816–821.
- Kearse, M.G., Green, K.M., Krans, A., Rodriguez, C.M., Linsalata, A.E., Goldstrohm, A.C., and Todd, P.K. (2016). CGG repeat-associated non-AUG translation utilizes a cap-dependent scanning mechanism of initiation to produce toxic proteins. *Mol. Cell* 62, 314–322.
- Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol.* 14, R36.
- Komor, A.C., Badran, A.H., and Liu, D.R. (2017). CRISPR-based technologies for the manipulation of eukaryotic genomes. *Cell* 168, 20–36.
- Krueger, F., and Andrews, S.R. (2011). Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics* 27, 1571–1572.
- Kumari, D., and Usdin, K. (2016). Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27. *Hum. Mol. Genet.* 25, 3689–3698.
- Lee, T.I., Johnstone, S.E., and Young, R.A. (2006). Chromatin immunoprecipitation and microarray-based analysis of protein location. *Nat. Protoc.* 1, 729–748.
- Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res.* 41, e108.
- Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930.
- Lister, R., Pelizzola, M., Downen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q.M., et al. (2009). Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 462, 315–322.
- Lister, R., Mukamel, E.A., Nery, J.R., Urich, M., Puddifoot, C.A., Johnson, N.D., Lucero, J., Huang, Y., Dwork, A.J., Schultz, M.D., et al. (2013). Global epigenomic reconfiguration during mammalian brain development. *Science* 341, 1237905.
- Liu, X.S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R.A., and Jaenisch, R. (2016). Editing DNA Methylation in the Mammalian Genome. *Cell* 167, 233–247.e17.
- Long, C., Amoasii, L., Mireault, A.A., McAnally, J.R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J.M., Bassel-Duby, R., and Olson, E.N. (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science* 351, 400–403.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. *Science* 339, 823–826.
- Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F., and Lindemann, L. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. *Neuron* 74, 49–56.
- Nelson, D.L., Orr, H.T., and Warren, S.T. (2013). The unstable repeats—three evolving faces of neurological disease. *Neuron* 77, 825–843.
- Nelson, C.E., Hakim, C.H., Ousterout, D.G., Thakore, P.I., Moreb, E.A., Castellanos Rivera, R.M., Madhavan, S., Pan, X., Ran, F.A., Yan, W.X., et al. (2016). In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science* 351, 403–407.
- Park, C.Y., Halevy, T., Lee, D.R., Sung, J.J., Lee, J.S., Yanuka, O., Benvenisty, N., and Kim, D.W. (2015a). Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. *Cell Rep.* 13, 234–241.
- Park, C.Y., Kim, D.H., Son, J.S., Sung, J.J., Lee, J., Bae, S., Kim, J.H., Kim, D.W., and Kim, J.S. (2015b). Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. *Cell Stem Cell* 17, 213–220.
- Pearson, C.E., Nichol Edamura, K., and Cleary, J.D. (2005). Repeat instability: mechanisms of dynamic mutations. *Nat. Rev. Genet.* 6, 729–742.
- Pugin, A., Faundes, V., Santa Maria, L., Curotto, B., Aliaga, S., Salas, I., Soto, P., Bravo, P., Peña, M.I., and Alliende, M.A. (2017). Clinical, molecular, and pharmacological aspects of FMR1 related disorders. *Neurologia* 32, 241–252.

- Rauch, B.J., Silvis, M.R., Hultquist, J.F., Waters, C.S., McGregor, M.J., Krogan, N.J., and Bondy-Denomy, J. (2017). Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* 168, 150–158.e10.
- Santoro, M.R., Bray, S.M., and Warren, S.T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. *Annu. Rev. Pathol.* 7, 219–245.
- Schultz, M.D., He, Y., Whitaker, J.W., Hariharan, M., Mukamel, E.A., Leung, D., Rajagopal, N., Nery, J.R., Urich, M.A., Chen, H., et al. (2015). Human body epigenome maps reveal noncanonical DNA methylation variation. *Nature* 523, 212–216.
- Sidorov, M.S., Auerbach, B.D., and Bear, M.F. (2013). Fragile X mental retardation protein and synaptic plasticity. *Mol. Brain* 6, 15.
- Smith, L.N., Jedynak, J.P., Fontenot, M.R., Hale, C.F., Dietz, K.C., Taniguchi, M., Thomas, F.S., Zirlin, B.C., Birnbaum, S.G., Huber, K.M., et al. (2014). Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration. *Neuron* 82, 645–658.
- Tabebordbar, M., Zhu, K., Cheng, J.K.W., Chew, W.L., Widrick, J.J., Yan, W.X., Maesner, C., Wu, E.Y., Xiao, R., Ran, F.A., et al. (2016). In vivo gene editing in dystrophic mouse muscle and muscle stem cells. *Science* 351, 407–411.
- Tabolacci, E., Palumbo, F., Nobile, V., and Neri, G. (2016). Transcriptional reactivation of the FMR1 gene: a possible approach to the treatment of the fragile X syndrome. *Genes (Basel)* 7, E49.
- Tassone, F., Iwahashi, C., and Hagerman, P.J. (2004). FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). *RNA Biol.* 1, 103–105.
- The Dutch-Belgian Fragile X Consortium (1994). Fmr1 knockout mice: a model to study fragile X mental retardation. *Cell* 78, 23–33.
- Todd, P.K., Oh, S.Y., Krans, A., He, F., Sellier, C., Frazer, M., Renoux, A.J., Chen, K.C., Scaglione, K.M., Basrur, V., et al. (2013). CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. *Neuron* 78, 440–455.
- Urbach, A., Bar-Nur, O., Daley, G.Q., and Benvenisty, N. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. *Cell Stem Cell* 6, 407–411.
- Verkerk, A.J., Pieretti, M., Sutcliffe, J.S., Fu, Y.H., Kuhl, D.P., Pizzuti, A., Reiner, O., Richards, S., Victoria, M.F., Zhang, F.P., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* 65, 905–914.
- Vojta, A., Dobrinić, P., Tadić, V., Bočkor, L., Korać, P., Julg, B., Klasić, M., and Zoldoš, V. (2016). Repurposing the CRISPR-Cas9 system for targeted DNA methylation. *Nucleic Acids Res.* 44, 5615–5628.
- Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* 153, 910–918.
- Windrem, M.S., Schanz, S.J., Morrow, C., Munir, J., Chandler-Militello, D., Wang, S., and Goldman, S.A. (2014). A competitive advantage by neonatally engrafted human glial progenitors yields mice whose brains are chimeric for human glia. *J. Neurosci.* 34, 16153–16161.
- Wojciechowska, M., and Krzyzosiak, W.J. (2011). Cellular toxicity of expanded RNA repeats: focus on RNA foci. *Hum. Mol. Genet.* 20, 3811–3821.
- Wu, H., and Zhang, Y. (2014). Reversing DNA methylation: mechanisms, genomics, and biological functions. *Cell* 156, 45–68.
- Xie, N., Gong, H., Suhl, J.A., Chopra, P., Wang, T., and Warren, S.T. (2016). Reactivation of FMR1 by CRISPR/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. *PLoS ONE* 11, e0165499.
- Xu, X., Tao, Y., Gao, X., Zhang, L., Li, X., Zou, W., Ruan, K., Wang, F., Xu, G.L., and Hu, R. (2016). A CRISPR-based approach for targeted DNA demethylation. *Cell Discov.* 2, 16009.
- Zeier, Z., Kumar, A., Bodhinathan, K., Feller, J.A., Foster, T.C., and Bloom, D.C. (2009). Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. *Gene Ther.* 16, 1122–1129.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-seq (MACS). *Genome Biol.* 9, R137.
- Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., Marro, S., Patzke, C., Acuna, C., Covy, J., et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. *Neuron* 78, 785–798.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-Cas9 (IF staining)	Active Motif	Cat#61577 (7A9-3A3)
Mouse monoclonal anti-Cas9 (ChIP)	Active Motif	Cat#61757 (8C1-F10)
Chicken polyclonal anti-GFP	Aves Labs	Cat#GFP-1020
Chicken polyclonal anti-MAP2	Encor Biotech	Cat# CPCA-MAP2
Rabbit polyclonal anti-FMRP (WB, ICC, IHC)	Cell Signaling	Cat#4317
Mouse monoclonal anti-FMRP (ICC, IHC)	Biolegend	Cat#834701
Mouse monoclonal anti-FMR1PolyG	EMD Millipore	Cat#MABN784
Goat polyclonal anti-mCherry	SICGEN	Cat#AB0040-200
Mouse monoclonal anti-RNA Polymerase II	Abcam	Cat#ab817
Rabbit polyclonal anti-H3K27Ac	Abcam	Cat#ab4729
Rabbit polyclonal anti-H3K9me3	Abcam	Cat#ab8898
Mouse monoclonal anti-H3K27me3	Abcam	Cat#ab6002
Rabbit polyclonal anti-H3K4me3	Millipore	Cat#07-473
Chemicals		
Doxycycline hyclate	Sigma Aldrich	Cat#D9891-100G
Critical Commercial Assays		
EpiTect Bisulfite Kit	QIAGEN	Cat#59104
EpiNext High-Sensitivity Bisulfite-Seq kit	EPIGENTEK	Cat#P-1056
EpiNext NGS Barcode Set-12	EPIGENTEK	Cat#P-1060
DNeasy Blood and Tissue Kit	QIAGEN	Cat#69504
Zymoclean Gel DNA Recovery Kit	Zymo Research	Cat#D4002
DNA Clean and Concentrator-5	Zymo Research	Cat#D4013
X-tremeGENE 9 DNA Transfection Reagent	Sigma Aldrich	Cat#6365809001
Direct-zol RNA Miniprep	Zymo Research	Cat#R2050
SuperScript III First-Strand Synthesis SuperMix	Life Technologies	Cat#18080400
Fast SYBR Green Master Mix	Life Technologies	Cat#4385618
Deposited Data		
Raw data files for sequencing	NCBI Gene Expression Omnibus	Database: GSE102655, GSE102684, GSE108171, GSE108498, GSE108577
Experimental Models: Organisms/Strains		
Mouse: NOD- <i>scid</i> IL2Rg ^{null} ,	Jackson Laboratories	Stock No: 005557
Experimental Models: Cell Lines		
FX52 iPSCs	(Urbach et al., 2010)	N/A
FXS iPSC (135.3)	(Brick et al., 2014)	N/A
FXS iPSC (FXS_SW)	(Xie et al., 2016)	N/A
Recombinant DNA		
Fuw-dCas9-Tet1-P2A-BFP	This paper	N/A
pgRNA (CGG sgRNA)	This paper	N/A
Fuw-AcrIIA4-P2A-GFP	This paper	N/A
See Plasmid Design and Construction in Method Details	N/A	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Sequence-Based Reagents		
See Tables S4 , S5 , and S6 for primer sequences	This paper	N/A
Software and Algorithms		
MACS (ChIP-seq algorithms)	N/A	http://liulab.dfci.harvard.edu/MACS/
ImageJ (Fiji)	NIH	http://imagej.net/Fiji

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Rudolf Jaenisch (jaenisch@wi.mit.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS**Mouse lines and breeding strategies**

An immuno-compromised mouse line (NOD-*scid* IL2Rg^{null}) was used for the transplantation experiment. Mice were housed in the animal facility at Whitehead Institute with sterilized water, food, and cages. Caretakers wear PPE in the mouse room. Male and female mice at the P1 stage were used for transplantation experiments, and no sex differences were observed. Mice were handled in accordance with institutional guidelines and approved by the Committee on Animal Care (CAC) and Department of Comparative Medicine (DCM) of Massachusetts Institute of Technology.

METHOD DETAILS**Plasmid design and construction**

PCR amplified Tet1 catalytic domain from pJFA344C7 (Addgene plasmid: 49236), Tet1 inactive catalytic domain from MLM3739 (Addgene plasmid: 49959), and tagBFP (synthesized gene block) were cloned into FUW vector (Addgene plasmid: 14882) with *AscI*, *EcoRI* and *Pf1MI* to package lentiviruses. The CGG sgRNA expression plasmids were cloned by inserting annealed oligos into modified pgRNA plasmid (Addgene plasmid: 44248) with *AarI* site. A synthetic gBlock encoding the bacteriophage AcrIIA4 purchased from IDT was cloned into a modified FUW vector with *AscI* and *EcoRI* to package lentiviruses. All constructs were sequenced before transfection. Primer information for sgRNA design and construction is listed in [Table S4](#). Related plasmids have been deposited into Addgene plasmid database.

Cell culture and lentivirus production

All the FXS iPSC lines were derived from male patients and reported previously (see [Key Resources Table](#)). The CGG repeat expansion mutations were verified by Claritas Genomics Inc with Asuragen AmpliDeX[®] mPCR approach and the mycoplasma test was negative. FXS iPSCs were cultured either with mTeSR1 medium (STEMCELL, #85850) or on irradiated mouse embryonic fibroblasts (MEFs) with standard hESCs medium: [DMEM/F12 (Invitrogen) supplemented with 15% fetal bovine serum (GIBCO HI FBS, 10082-147), 5% KnockOut Serum Replacement (Invitrogen), 2 mM L-glutamine (MPBio), 1% nonessential amino acids (Invitrogen), 1% penicillin-streptomycin (Lonza), 0.1 mM β-mercaptoethanol (Sigma) and 4 ng/ml FGF2 (R&D systems)]. Lentiviruses expressing dCas9-Tet1-P2A-BFP, sgRNAs, and AcrIIA4 were produced by transfecting HEK293T cells with FUW constructs or pgRNA constructs together with standard packaging vectors (pCMV-dR8.74 and pCMV-VSVG) followed by ultra-centrifugation-based concentration. Virus titer (T) was calculated based on the infection efficiency for 293T cells, where $T = (P \cdot N) / (V)$, T = titer (TU/ul), p = % of infection positive cells according to the fluorescence marker, N = number of cells at the time of transduction, V = total volume of virus used. Note TU stands for transduction unit. Lentiviruses labeling NPCs (EF1A-GFP and EF1A-RFP) were purchased from Cellomics Technology.

Multi-electrode array recording

Two- or four-week-old differentiating neuronal cultures were dissociated using Accutase and 5 X 10⁵ cells were plated on each single well in the PEI-coated Axion Biosystems # M768-GL1-30Pt200 arrays. Recordings of spontaneous activities during a 5-minute period were performed on days indicated. Biological triplicates for each type of neurons were included.

Transplantation of FXS NPCs into mouse brain

Cultured human neural precursor cells (NPC) were dissociated using Accutase (Life Technologies) and resuspended in phosphate buffer saline without calcium and magnesium prior to injection, at a concentration of 6 x 10⁴ cells/μL. NOD-*scid* IL2Rg^{null} mouse

pups of either sex were manually injected within a day of birth with a total of 300,000 hNPC dispersed over five injection sites, as described previously (Windrem et al., 2014). The mice were perfused with 4% paraformaldehyde for immunohistochemistry at 1 month of age ($n = 3$ mice) and 3 months of age ($n = 2$ mice), and 100 μm -thick brain sections were prepared for immunofluorescence analyses with the antibodies indicated.

Immunocytochemistry, immunohistochemistry, microscopy, and image analysis

FXS iPSCs and neurons were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature. Cells were permeabilized with PBST (1 x PBS solution with 0.1% Triton X-100) before blocking with 10% Normal Donkey Serum (NDS) in PBST. Cells were then incubated with appropriately diluted primary antibodies in PBST with 5% NDS for 1 hour at room temperature or 12 hours at 4°C, washed with PBST for 3 times at room temperature and then incubated with desired secondary antibodies in TBST with 5% NDS and DAPI to counter stain the nuclei. Mouse brain slices were incubated for an hour in PBS with 0.5% Triton and 3% normal serum. Slices were then incubated with desired primary antibodies in the same solution for 72 hours at 4°C, washed with PBS for 3 times at room temperature and then incubated with secondary antibodies in PBS for 24 hours away from light at room temperature. Staining of the nuclei with DAPI was then performed. Sections were washed 3 times with PBS before slide mounting. The following antibodies were used in this study: Chicken anti-GFP (1:1000, Aves Labs), Rabbit anti-FMRP (1:50, Cell Signaling), Chicken anti-MAP2 (1:1000, Encor Biotech), Goat anti-mCherry (1:1000, SICGEN). Images were captured on a Zeiss LSM710 confocal microscope and processed with Zen software, ImageJ/Fiji, and Adobe Photoshop. For imaging-based quantification, unless otherwise specified, 3-5 representative images were quantified and data were plotted as mean \pm SD with Excel or Graphpad Prism.

FACS analysis

To isolate the infection-positive cell after lentiviral transduction, the treated cells were dissociated with trypsin and single-cell suspensions were prepared in growth medium subject to a BD FACSAria cell sorter according to the manufacturer's protocol at the Whitehead Institute Flow Cytometry Core. Data were analyzed with FlowJo software.

Western blot

Cells were lysed by RIPA buffer with proteinase inhibitor (Invitrogen), and subject to standard immunoblotting analysis. Mouse anti-Cas9 (1:1000, Active Motif), mouse α -Tubulin (1:1000, Sigma), mouse anti-FMR1polyG (1:1000, EMD Millipore), rabbit anti-FMRP (1:100, Cell Signaling) antibodies were used.

RT-qPCR

Cells were harvested using Trizol followed by Direct-zol (Zymo Research), according to manufacturer's instructions. RNA was converted to cDNA using First-strand cDNA synthesis (Invitrogen SuperScript III). Quantitative PCR reactions were prepared with SYBR Green (Invitrogen), and performed in 7900HT Fast ABI instrument. Primer information for RT-qPCR is listed in Table S5.

Chromatin Immunoprecipitation

Chromatin immunoprecipitation (ChIP) was performed as described in (Lee et al., 2006) with a few adaptations. Cells were crosslinked for 15 minutes at room temperature by the addition of one-tenth volume of fresh 11% formaldehyde solution (11% formaldehyde, 50 mM HEPES pH 7.3, 100 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0) to the growth media followed by 5 min quenching with 125 mM glycine. Cells were rinsed twice with 1X PBS and harvested using a silicon scraper and flash frozen in liquid nitrogen. Frozen crosslinked cells were stored at -80°C . For immunoprecipitation of lysate from 100 million cells, 50 μl of Protein G Dynabeads (Life Technologies #10009D) and 5 μg of antibody were prepared as follows. Dynabeads were washed 3X for 5 minutes with 0.5% BSA (w/v) in PBS. Magnetic beads were bound with the antibody overnight at 4°C, and then washed 3X with 0.5% BSA (w/v) in PBS.

Cells were prepared for ChIP as follows. All buffers contained freshly prepared 1 x cOmplete protease inhibitors (Roche, 11873580001). Frozen crosslinked cells were thawed on ice and then resuspended in lysis buffer I (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1 x protease inhibitors) and rotated for 10 minutes at 4°C, then spun at 1350 *rcf.* for 5 minutes at 4°C. The pellet was resuspended in lysis buffer II (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 x protease inhibitors) and rotated for 10 minutes at 4°C and spun at 1350 *rcf.* for 5 minutes at 4°C. The pellet was resuspend in sonication buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA pH 8.0, 0.1% SDS, and 1% Triton X-100, 1 x protease inhibitors) and then sonicated on a Misonix 3000 sonicator for 10 cycles at 30 s each on ice (18-21 W) with 60 s on ice between cycles. Sonicated lysates were cleared once by centrifugation at 16,000 *rcf.* for 10 minutes at 4°C. 50 μl was reserved for input, and then the remainder was incubated overnight at 4°C with magnetic beads bound with antibody to enrich for DNA fragments bound by the indicated factor. Beads were washed twice with each of the following buffers: wash buffer A (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8.0, 0.1% Na-Deoxycholate, 1% Triton X-100, 0.1% SDS), wash buffer B (50 mM HEPES-KOH pH 7.9, 500 mM NaCl, 1 mM EDTA pH 8.0, 0.1% Na-Deoxycholate, 1% Triton X-100, 0.1% SDS), wash buffer C (20 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA pH 8.0, 0.5% Na-Deoxycholate, 0.5% IGEPAL C-630 0.1% SDS), wash buffer D (TE with 0.2% Triton X-100), and TE buffer. DNA was eluted off the beads by incubation at 65°C for 1 hour with intermittent vortexing in 200 μl elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS). Cross-links were reversed overnight at

DNA Methylation analysis

Pyro-seq of all bisulfite converted genomic DNA samples were performed with PyroMark Q48 Autoprep (QIAGEN) according to the manufacturer's instructions. Primers information for pyro-seq is listed in [Table S6](#). Methylation analysis of CGG trinucleotide repeats: Methylation status of CGG repeats were analyzed by Claritas Genomics Inc. with Asuragen AmplideX® mPCR approach.

RNA-seq and analysis

The 40 bp single-end reads from Illumina had good quality by checking with FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were mapped to hg19 using TopHat v2.1.1 ([Kim et al., 2013](#)) with options as “solexa1.3-quals” mode and “no-novel-juncs.” The gene model for TopHat was created by merging knownGene in gtf format with kgXref table. Both knownGene and kgXref were downloaded from UCSC table browser in hg19 assembly. The read counts were obtained using featureCounts ([Liao et al., 2014](#)) function from Subread package ([Liao et al., 2013](#)) with strandness option as $-r$ 2. Reads were normalized with DESeq2 ([Love et al., 2014](#)). The biological replicates in the neuron samples, processed at different time periods, have batch effect as suggested by principle component analysis. Consequently, Combat was used for reducing this batch effect. The log₂ values of the normalized reads were plotted in the scatterplots in [Figures 2F](#), and [5E](#). To avoid log₀ as undefined value, the number of reads for each gene was increased by one. Raw data along with gene expression levels were deposited to NCBI Gene Expression Omnibus GSE108498.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical parameters including the exact value of n and measures (mean \pm SD) and statistical significance are reported in the Figures and the Figure Legends. Data are judged to be statistically significant when $p < 0.05$ by two-tailed Student's T-Test or 2-way ANOVA, where appropriate.

DATA AND SOFTWARE AVAILABILITY

The accession numbers for the raw data files for sequencing analysis reported in this paper are NCBI: GSE102655, GSE102684, GSE108171, and GSE108498. These SubSeries are linked to one SuperSeries GSE108577.




Figure S1. Reactivation of *FMR1* by dCas9-Tet1 with CGG sgRNA in Multiple FXS iPSC Lines, Related to Figures 1 and 2

(A) One previously reported FXS iPSC line (135.3) with more than 450 CGG repeats was infected with lentiviruses expressing dCas9-Tet1-P2A-BFP (dC-T) with a mCherry expressing sgRNA targeting the CGG repeats "GGCGGCGGCGGCGGCGGCGGNGG" (CGG sgRNA) or lentiviruses expressing dCas9 fused with a catalytically dead Tet1 (dC-dT) with the same sgRNA. Double positive (BFP+; mCherry+) cells were isolated by FACS after infection. The expression level of *FMR1* were quantified by qPCR analysis and compared to an isogenic line with shortened CGG repeat expansion, and shown as the mean of relative percentages to the one in WIBR1 hESCs \pm SD of two biological replicates.

(B) Another previously reported FXS iPSC line (SW) with more than 450 CGG repeats was used to examine *FMR1* expression as did in B. The expression level of *FMR1* were quantified by qPCR analysis and compared to an isogenic line with shortened CGG repeat expansion, and shown as the mean of relative percentages to the one in WIBR1 hESCs \pm SD of two biological replicates.

(C) FX52 iPSCs were infected with different ratios of lentiviruses expressing dCas9-Tet1-P2A-BFP (dC-T) and a CGG sgRNA. Infected cells were harvested for qPCR analysis of *FMR1* expression at various time points. Shown is the mean of relative percentages to the one in a CGG deletion FX52 iPSC line \pm SD of two biological replicates.